4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Estrella Immunopharma, Inc. (ESLA) operates in the Biotechnology industry and is headquartered in EmeryVille, United States. Its market capitalization is roughly $42 million. In the fiscal year ended 2025-12-31, ESLA reported $0M in revenue and ($13M) in net income.
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($13M) | ($7M) | ($11M) | ($2M) |
| Net Income | ($13M) | ($7M) | ($11M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($2M) | ($1M) | ($5M) | ($6M) | ($2M) |
| Net Income | ($2M) | ($1M) | ($5M) | ($6M) | ($2M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| Total Assets | $3M | $4M | $3M | $5M |
| Total Liabilities | $14M | $0M | $15M | $6M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ESLA viewer.
About TickerBase · Data methodology & sources